
|Videos|July 14, 2022
Dr. Barata stresses significance of tumor sequencing in urothelial carcinoma
Author(s)Urology Times staff
“The real-world data suggest that the use of tumor sequencing is definitely suboptimal,” says Pedro C. Barata, MD, MSc.
Advertisement
Pedro C. Barata, MD, MSc, an associate professor of Medicine in Hematology and Medical Oncology at the Tulane University School of Medicine, discusses the importance of tumor sequencing to the implementation of precision medicine for patients with urothelial carcinoma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants tentative approval to generic olaparib tablets across previously approved indications
2
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
3
FDA grants priority review to talazoparib plus enzalutamide for HRR gene-altered mCSPC
4
Published data support PSMA-PET–guided selection for 177Lu-rosopatamab tetraxetan in mCRPC
5












